المؤلفون: Fady Ghali, Sarah K. Holt, Elizabeth L. Koehne, Jonathan J. Chen, Emily S. Weg, Jay J. Liao, Jing Zeng, Petros Grivas, Jessica E. Hawley, Andrew C. Hsieh, Robert Bruce Montgomery, Jonathan L. Wright

المصدر: Frontiers in Oncology, Vol 14 (2024)

مصطلحات موضوعية: bladder cancer, organ-preservation, radiation, chemotherapy, trimodal therapy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

العلاقة: https://www.frontiersin.org/articles/10.3389/fonc.2024.1341655/fullTest; https://doaj.org/toc/2234-943XTest

الوصول الحر: https://doaj.org/article/ff2a92a4e4a9438ba12fcff2fe11e524Test

المؤلفون: Xiaozhe Su, Caitao Dong, Wenbiao Liao, Wentao Liu

المصدر: World Journal of Surgical Oncology, Vol 21, Iss 1, Pp 1-9 (2023)

مصطلحات موضوعية: Muscle-invasive bladder cancer, Trimodal therapy, Radical cystectomy, Meta-analysis, Surgery, RD1-811, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/1477-7819Test

الوصول الحر: https://doaj.org/article/7b1fbf3a97f24fbeaf1c07d190210a16Test

المؤلفون: Mario de Angelis, Andrea Baudo, Carolin Siech, Letizia Maria Ippolita Jannello, Francesco Di Bello, Jordan A. Goyal, Zhe Tian, Nicola Longo, Ottavio de Cobelli, Felix K. H. Chun, Fred Saad, Shahrokh F. Shariat, Luca Carmignani, Giorgio Gandaglia, Marco Moschini, Francesco Montorsi, Alberto Briganti, Pierre I. Karakiewicz

المصدر: Cancers, Vol 16, Iss 7, p 1292 (2024)

مصطلحات موضوعية: bladder cancer, MIBC, urothelial carcinoma, non-surgical management, trimodal therapy, TMT, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

العلاقة: https://www.mdpi.com/2072-6694/16/7/1292Test; https://doaj.org/toc/2072-6694Test

الوصول الحر: https://doaj.org/article/b318cbc0f4e44c458c4dcec94ed276d1Test

المؤلفون: C.F. Stockem, J.J.J. Mellema, B.W.G. van Rhijn, T.N. Boellaard, M.L. van Montfoort, S. Balduzzi, J.L. Boormans, M. Franckena, R.P. Meijer, D.G.J. Robbrecht, B.B.M. Suelmann, E.E. Schaake, M.S. van der Heijden

المصدر: Frontiers in Oncology, Vol 13 (2023)

مصطلحات موضوعية: Muscle-invasive bladder cancer, bladder preservation, immune checkpoint blockade, chemoradiation, trimodal therapy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

العلاقة: https://www.frontiersin.org/articles/10.3389/fonc.2023.1246603/fullTest; https://doaj.org/toc/2234-943XTest

الوصول الحر: https://doaj.org/article/2561f22f0c4a47d3a373cdba195158f6Test

المؤلفون: Moayid Fallatah, Ali S Alkahtani, Majed Alrumayyan, Mohammed F Alotaibi, Sultan Alkhateeb, Alaa Ahmed Mokhtar, Waleed Altaweel

المصدر: Urology Annals, Vol 15, Iss 4, Pp 406-411 (2023)

مصطلحات موضوعية: muscle invasive bladder cancer, radical cystectomy, treatment outcome, trimodal therapy, urothelial neoplasms, Diseases of the genitourinary system. Urology, RC870-923

وصف الملف: electronic resource

العلاقة: http://www.urologyannals.com/article.asp?issn=0974-7796;year=2023;volume=15;issue=4;spage=406;epage=411;aulast=FallatahTest; https://doaj.org/toc/0974-7796Test; https://doaj.org/toc/0974-7834Test

الوصول الحر: https://doaj.org/article/25788a16e9134f8c81d779048cc498ccTest

المؤلفون: Wentai Shangguan, Jintao Hu, Yingwei Xie, Zhiliang Chen, Qiyu Zhong, Zaosong Zheng, Dingjun Zhu, Yishan Zhang, Jingying Yang, Jinli Han, Wenlian Xie

المصدر: Cancer Medicine, Vol 11, Iss 12, Pp 2356-2365 (2022)

مصطلحات موضوعية: conditional survival, nonmetastatic muscle‐invasive bladder cancer, prognostic factor, survival analysis, trimodal therapy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/2045-7634Test

الوصول الحر: https://doaj.org/article/f65b57fe21494f848d2546c72d47f2c1Test

المؤلفون: Stockem, C. F., Mellema, J. J.J., van Rhijn, B. W.G., Boellaard, T. N., van Montfoort, M. L., Balduzzi, S., Boormans, J. L., Franckena, M., Meijer, R. P., Robbrecht, D. G.J., Suelmann, B. B.M., Schaake, E. E., van der Heijden, M. S.

المساهمون: MS Urologische Oncologie, Cancer, MS Medische Oncologie

مصطلحات موضوعية: bladder preservation, chemoradiation, immune checkpoint blockade, Muscle-invasive bladder cancer, trimodal therapy, Oncology, Cancer Research

وصف الملف: application/pdf

العلاقة: https://dspace.library.uu.nl/handle/1874/450053Test

الإتاحة: https://dspace.library.uu.nl/handle/1874/450053Test

المؤلفون: A. V. Troianov, I. O. Dementev, I. N. Zaborsky, V. S. Chaykov, O. B. Karyakin, Yu. V. Gumenetskaya, А. В. Троянов, И. О. Дементьев, И. Н. Заборский, В. С. Чайков, О. Б. Карякин, Ю. В. Гуменецкая

المصدر: Research and Practical Medicine Journal; Том 10, № 1 (2023); 111-125 ; Research'n Practical Medicine Journal; Том 10, № 1 (2023); 111-125 ; 2410-1893 ; 10.17709/2410-1893-2023-10-1

مصطلحات موضوعية: комбинированное лечение, organ-preserving treatment, trimodal therapy, combined treatment, органосохраняющее лечение, тримодальная терапия

وصف الملف: application/pdf

العلاقة: https://www.rpmj.ru/rpmj/article/view/864/543Test; Prout GR, Marshall VF. The prognosis with untreated bladder tumors. Cancer. 1956;9(3):551–8.; Fedeli U, Fedewa SA, Ward EM. Treatment of muscle invasive bladder cancer: evidence from the National Cancer Database, 2003 to 2007. J Urol. 2011 Jan;185(1):72–78. https://doi.org/10.1016/j.juro.2010.09.015Test; American Cancer Society. Cancer Facts and Figures 2016. Atlanta: American Cancer Society; 2016. https://doi.org/10.3322/caac.21332Test; Shabsigh A, Korets R, Vora KC, Brooks CM, Cronin AM, Savage C, et al. Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur Urol. 2009 Jan;55(1):164–174. https://doi.org/10.1016/j.eururo.2008.07.031Test; Gandaglia G, Varda B, Sood A, Pucheril D, Konijeti R, Sammon JD, et al. Short‑term perioperative outcomes of patients treated with radical cystectomy for bladder cancer included in the National Surgical Quality Improvement Program (NSQIP) database. Can Urol Assoc J. 2014 Sep;8(9‑10):E681–687. https://doi.org/10.5489/cuaj.2069Test; Shimko MS, Tollefson MK, Umbreit EC, Farmer SA, Blute ML, Frank I. Long‑term complications of conduit urinary diversion. J Urol. 2011 Feb;185(2):562–567. https://doi.org/10.1016/j.juro.2010.09.096Test; NCCN Clinical Practice Guildelines in Oncology: Bladder Cancer. Version 1.2022. February 11, 2022. National Comprehensive Cancer Network, Inc. Retrieved from https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdfTest; EAU Guidelines. Edn. presented at the EAU Annual Congress Amsterdam 2022. ISBN 978‑94‑92671‑16‑5.; Smith ZL, Christodouleas JP, Keefe SM, Malkowicz SB, Guzzo TJ. Bladder preservation in the treatment of muscle‑invasive bladder cancer (MIBC): a review of the literature and a practical approach to therapy. BJU Int. 2013 Jul;112(1):13–25. https://doi.org/10.1111/j.1464Test‑410x.2012.11762.x; Gakis G, Efstathiou J, Lerner SP, Cookson MS, Keegan KA, Guru KA, et al.; International Consultation on Urologic Disease‑European Association of Urology Consultation on Bladder Cancer 2012. ICUD‑EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle‑invasive urothelial carcinoma of the bladder. Eur Urol. 2013 Jan;63(1):45–57. https://doi.org/10.1016/j.eururo.2012.08.009Test; Biagioli MC, Fernandez DC, Spiess PE, Wilder RB. Primary bladder preservation treatment for urothelial bladder cancer. Cancer Control. 2013 Jul;20(3):188–199. https://doi.org/10.1177/107327481302000307Test; Herr HW. Transurethral resection of muscle‑invasive bladder cancer: 10‑year outcome. J Clin Oncol. 2001 Jan 1;19(1):89–93. https://doi.org/10.1200/jco.2001.19.1.89Test; Holmäng S, Hedelin H, Anderström C, Johansson SL. Long‑term followup of all patients with muscle invasive (stages T2, T3 and T4) bladder carcinoma in a geographical region. J Urol. 1997 Aug;158(2):389–392.; Solsona E, Iborra I, Collado A, Rubio‑Briones J, Casanova J, Calatrava A. Feasibility of radical transurethral resection as monotherapy for selected patients with muscle invasive bladder cancer. J Urol. 2010 Aug;184(2):475–480. https://doi.org/10.1016/j.juro.2010.04.008Test; Volkmer BG, Kuefer R, Bartsch G Jr, Straub M, de Petriconi R, Gschwend JE, Hautmann RE. Effect of a pT0 cystectomy specimen without neoadjuvant therapy on survival. Cancer. 2005 Dec 1;104(11):2384–2391. https://doi.org/10.1002/cncr.21475Test; Milosevic M, Gospodarowicz M, Zietman A, Abbas F, Haustermans K, Moonen L, Rödel C, Schoenberg M, Shipley W. Radiotherapy for bladder cancer. Urology. 2007 Jan;69(1 Suppl):80–92. https://doi.org/10.1016/j.urology.2006.05.060Test; Søndergaard J, Holmberg M, Jakobsen AR, Agerbæk M, Muren LP, Høyer M. A comparison of morbidity following conformal versus intensity‑modulated radiotherapy for urinary bladder cancer. Acta Oncol. 2014 Oct;53(10):1321–1328. https://doi.org/10.3109/0284186x.2014.928418Test; Tonoli S, Bertoni F, De Stefani A, Vitali E, De Tomasi D, Caraffini B, et al. Radical radiotherapy for bladder cancer: retrospective analysis of a series of 459 patients treated in an Italian institution. Clin Oncol (R Coll Radiol). 2006 Feb;18(1):52–59. https://doi.org/10.1016/j.clon.2005.06.015Test; Efstathiou JA, Spiegel DY, Shipley WU, Heney NM, Kaufman DS, Niemierko A, et al. Long‑term outcomes of selective bladder preservation by combined‑modality therapy for invasive bladder cancer: the MGH experience. Eur Urol. 2012 Apr;61(4):705–711. https://doi.org/10.1016/j.eururo.2011.11.010Test; Mak RH, Hunt D, Shipley WU, Efstathiou JA, Tester WJ, Hagan MP, Kaufman DS, Heney NM, Zietman AL. Long‑term outcomes in patients with muscle‑invasive bladder cancer after selective bladder‑preserving combined‑modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol. 2014 Dec 1;32(34):3801–3809. https://doi.org/10.1200/jco.2014.57.5548Test; James ND, Hussain SA, Hall E, Jenkins P, Tremlett J, Rawlings C, et al.; BC2001 Investigators. Radiotherapy with or without chemotherapy in muscle‑invasive bladder cancer. N Engl J Med. 2012 Apr 19;366(16):1477–1488. https://doi.org/10.1056/nejmoa1106106Test; Tarin TV, Power NE, Ehdaie B, Sfakianos JP, Silberstein JL, Savage CJ, et al. Lymph node‑positive bladder cancer treated with radical cystectomy and lymphadenectomy: effect of the level of node positivity. Eur Urol. 2012 May;61(5):1025–1030. https://doi.org/10.1016/j.eururo.2012.01.049Test; Huddart RA, Hall E, Hussain SA, Jenkins P, Rawlings C, Tremlett J, et al. Randomized noninferiority trial of reduced high‑dose volume versus standard volume radiation therapy for muscle‑invasive bladder cancer: results of the BC2001 trial (CRUK/01/004). Int J Radiat Oncol Biol Phys. 2013 Oct 1;87(2):261–269. https://doi.org/10.1016/j.ijrobp.2013.06.2044Test. Erratum in: Int J Radiat Oncol Biol Phys. 2013 Dec 1;87(5):860; Ploussard G, Daneshmand S, Efstathiou JA, Herr HW, James ND, Rödel CM, Shariat SF, Shipley WU, Sternberg CN, Thalmann GN, Kassouf W. Critical analysis of bladder sparing with trimodal therapy in muscle‑invasive bladder cancer: a systematic review. Eur Urol. 2014 Jul;66(1):120–137. https://doi.org/10.1016/j.eururo.2014.02.038Test; Hagan MP, Winter KA, Kaufman DS, Wajsman Z, Zietman AL, Heney NM, Toonkel LM, Jones CU, Roberts JD, Shipley WU. RTOG 97‑06: initial report of a phase I‑II trial of selective bladder conservation using TURBT, twice‑daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):665–672. https://doi.org/10.1016/s0360Test‑3016(03)00718‑1; Kaufman DS, Winter KA, Shipley WU, Heney NM, Wallace HJ 3rd, Toonkel LM, et al. Phase I‑II RTOG study (99‑06) of patients with muscle‑invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice‑daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy. Urology. 2009 Apr;73(4):833–837. https://doi.org/10.1016/j.urology.2008.09.036Test; Mitin T, Hunt D, Shipley WU, Kaufman DS, Uzzo R, Wu CL, et al. Transurethral surgery and twice‑daily radiation plus paclitaxel‑cisplatin or fluorouracil‑cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomized multicentre phase 2 trial. Lancet Oncol. 2013 Aug;14(9):863–872. https://doi.org/10.1016/s1470Test‑2045(13)70255‑9; Kaufman DS, Winter KA, Shipley WU, Heney NM, Chetner MP, Souhami L, et al. The initial results in muscle‑invading bladder cancer of RTOG 95‑06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5‑fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response. Oncologist. 2000;5(6):471–476. https://doi.org/10.1634/theoncologist.5Test‑6‑471; Coppin CM, Gospodarowicz MK, James K, Tannock IF, Zee B, Carson J, et al. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1996 Nov;14(11):2901–2907. https://doi.org/10.1200/jco.1996.14.11.2901Test; Azria D, Riou O, Rebillard X, Thezenas S, Thuret R, Fenoglietto P, Pouessel D, Culine S. Combined chemoradiation therapy with twice‑weekly gemcitabine and cisplatin for organ preservation in muscle‑invasive bladder cancer: long‑term results of a phase 1 trial. Int J Radiat Oncol Biol Phys. 2014 Mar 15;88(4):853–859. https://doi.org/10.1016/j.ijrobp.2013.11.016Test; Tester W, Caplan R, Heaney J, Venner P, Whittington R, Byhardt R, et al. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802. J Clin Oncol. 1996 Jan;14(1):119–126. https://doi.org/10.1200/jco.1996.14.1.119Test; Tester W, Porter A, Asbell S, Coughlin C, Heaney J, Krall J, et al. Combined modality program with possible organ preservation for invasive bladder carcinoma: results of RTOG protocol 85‑12. Int J Radiat Oncol Biol Phys. 1993 Apr 2;25(5):783–790. https://doi.org/10.1016/0360Test‑3016(93)90306‑g; Shipley WU, Winter KA, Kaufman DS, Lee WR, Heney NM, Tester WR, et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89‑03. J Clin Oncol. 1998 Nov;16(11):3576–3583. https://doi.org/10.1200/jco.1998.16.11.3576Test; De Santis M, Bachner M, Cerveny M, Kametriser G, Steininger T, Königsberg R, et al. Combined chemoradiotherapy with gemcitabine in patients with locally advanced inoperable transitional cell carcinoma of the urinary bladder and/or in patients ineligible for surgery: a phase I trial. Ann Oncol. 2014 Sep;25(9):1789–1794. https://doi.org/10.1093/annonc/mdu209Test; von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000 Sep;18(17):3068–3077. https://doi.org/10.1200/jco.2000.18.17.3068Test; Mitin T, George A, Zietman AL, Heney NM, Kaufman DS, Uzzo RG, et al. Long‑Term Outcomes Among Patients Who Achieve Complete or Near‑Complete Responses After the Induction Phase of Bladder‑Preserving Combined‑Modality Therapy for Muscle‑Invasive Bladder Cancer: A Pooled Analysis of NRG Oncology/RTOG 9906 and 0233. Int J Radiat Oncol Biol Phys. 2016 Jan 1;94(1):67–74. https://doi.org/10.1016/j.ijrobp.2015.09.030Test; Гуменецкая Ю. В., Попов А. М., Карякин О. Б., Мардынский Ю. С., Гулидов И. А. Результаты комбинированного лечения (трансуретральной резекции опухоли с последующей дистанционной лучевой терапией) у больных мышечно‑инвазивным раком мочевого пузыря. Сибирский онкологический журнал. 2012;50(2):6–10.; Гуменецкая Ю. В., Попов А. М., Карякин О. Б. Анализ осложнений комплексного органосохраняющего лечения больных мышечно‑инвазивным раком мочевого пузыря. Актуальные вопросы диагностики и лечения местно‑распространенного и метастатического рака почки, мочевого пузыря и предстательной железы. Материалы конференции онкоурологов стран СНГ, Украина, Киев, 2012, с. 33–34.; Гуменецкая Ю.В.,Попов А.М.,Карякин О.Б.Отдаленные результаты комплексного органосохраняющего лечения больных мышечно‑инвазивным раком мочевого пузыря. Актуальные вопросы диагностики и лечения местно‑распространенного и метастатического рака почки, мочевого пузыря и предстательной железы: материалы конференции онкоурологов стран СНГ, Украина, Киев, 2012, с. 34.; Карякин О. Б., Мардынский Ю. С., Гришин Г. Н., Сахарова О. В., Теплякова Ю. В. Комбинированное лечение местнораспространенного рака мочевого пузыря. Урология и нефрология. 1996;1:17–19.; Карякин О. Б. Органосохранная тактика при инвазивном раке мочевого пузыря: «за» и «против». Практическая онкология. 2003;4(4):252–254.; Карякин О. Б., Сафиуллин К. Н., Полтораков А. М., Теплякова Ю. В. Комбинированное лечение местнораспространенного рака мочевого пузыря. Медицинская радиология. 1992;37(11–12):12–13.; Karyakin O, Popov A. Conservative treatment of invasive bladder cancer. European Urology Supplements. 2004;3(2):178.; Гуменецкая Ю. В., Попов А. М., Карякин О. Б., Гулидов И. А. Результаты химиолучевого лечения мышечно‑инвазивного рака мочевого пузыря. Сибирский онкологический журнал. 2013;6:9–13.; Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, et al. Radical cystectomy in the treatment of invasive bladder cancer: long‑term results in 1,054 patients. J Clin Oncol. 2001 Feb 1;19(3):666–675. https://doi.org/10.1200/jco.2001.19.3.666Test; Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003 Aug 28;349(9):859–866. https://doi.org/10.1056/nejmoa022148Test. Erratum in: N Engl J Med. 2003 Nov 6;349(19):1880; Dalbagni G, Genega E, Hashibe M, Zhang ZF, Russo P, Herr H, Reuter V. Cystectomy for bladder cancer: a contemporary series. J Urol. 2001 Apr;165(4):1111–1116.; Gloeckler‑Ries LA, Young JL, Keel GE, et al. (eds). SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988‑2001, Patient and Tumor Characteristics. National Cancer Institute, SEER Program, NIH Pub. No. 07‑6215, Bethesda, MD, 2007.; Cahn DB, Handorf E, Nordsiek M, et al. Contemporary Utilization Trends and Survival Outcomes in Patients Undergoing Radical Cystectomy and Bladder Preservation Therapy for Muscle Invasive Bladder Cancer. J Clin Oncol. 2016;34(suppl 2S, abstr 387). https://doi.org/10.1002/cncr.30900Test; Giacalone NJ, Shipley WU, Clayman RH, Niemierko A, Drumm M, Heney NM, et al. Long‑term Outcomes After Bladder‑preserving Tri‑modality Therapy for Patients with Muscle‑invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. Eur Urol. 2017 Jun;71(6):952–960. https://doi.org/10.1016/j.eururo.2016.12.020Test; Miyamoto D, Drumm M, Clayman RH. Outcomes and tolerability of selective bladder preservation by combined modality therapy for invasive bladder cancer in elderly patients. J Clin Oncolю 2017;35 (suppl 6S; abstract 316). https://doi.org/10.1200/jco.2017.35.6_suppl.316Test; Takayanagi A, Masumori N, Takahashi A, Takagi Y, Tsukamoto T. Upper urinary tract recurrence after radical cystectomy for bladder cancer: incidence and risk factors. Int J Urol. 2012 Mar;19(3):229–233. https://doi.org/10.1111/j.1442Test‑2042.2011.02916.x; Efstathiou JA, Bae K, Shipley WU, Kaufman DS, Hagan MP, Heney NM, Sandler HM. Late pelvic toxicity after bladder‑sparing therapy in patients with invasive bladder cancer: RTOG 89‑03, 95‑06, 97‑06, 99‑06. J Clin Oncol. 2009 Sep 1;27(25):4055–4061. https://doi.org/10.1200/jco.2008.19.5776Test; Zietman AL, Sacco D, Skowronski U, Gomery P, Kaufman DS, Clark JA, Talcott JA, Shipley WU. Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long‑term survivors. J Urol. 2003 Nov;170(5):1772–1776. https://doi.org/10.1097/01.ju.0000093721.23249.c3Test; Ramani VA, Maddineni SB, Grey BR, Clarke NW. Differential complication rates following radical cystectomy in the irradiated and nonirradiated pelvis. Eur Urol. 2010 Jun;57(6):1058–1063. https://doi.org/10.1016/j.eururo.2009.12.002Test; Eswara JR, Efstathiou JA, Heney NM, Paly J, Kaufman DS, McDougal WS, et al. Complications and long‑term results of salvage cystectomy after failed bladder sparing therapy for muscle invasive bladder cancer. J Urol. 2012 Feb;187(2):463–468. https://doi.org/10.1016/j.juro.2011.09.159Test; Iwai A, Koga F, Fujii Y, Masuda H, Saito K, Numao N, Sakura M, Kawakami S, Kihara K. Perioperative complications of radical cystectomy after induction chemoradiotherapy in bladder‑sparing protocol against muscle‑invasive bladder cancer: a single institutional retrospective comparative study with primary radical cystectomy. Jpn J Clin Oncol. 2011 Dec;41(12):1373–1379. https://doi.org/10.1093/jjco/hyr150Test; Kang JJ,Steinberg ML,Kupelian P,Alexander S,King CR.Whole Versus Partial Bladder Radiation:Use of an Image‑guided Hypofractionated IMRT Bladder‑preservation Protocol.Am J Clin Oncol.2018 Feb;41(2):107–114.https://doi.org/10.1097/coc.0000000000000237Test; https://www.rpmj.ru/rpmj/article/view/864Test

الإتاحة: https://doi.org/10.17709/2410-1893-2023-10-1-10Test
https://doi.org/10.17709/2410-1893-2023-10-1Test
https://doi.org/10.1016/j.juro.2010.09.015Test
https://doi.org/10.3322/caac.21332Test
https://doi.org/10.1016/j.eururo.2008.07.031Test
https://doi.org/10.5489/cuaj.2069Test
https://doi.org/10.1016/j.juro.2010.09.096Test
https://doi.org/10.1111/j.1464Test‑410x.2012.11762.x
https://doi.org/10.1016/j.eururo.2012.08.009Test
https://doi.org/10.1177/107327481302000307Test

المؤلفون: Abhishek Kumar, Daniel R. Cherry, Patrick T. Courtney, Vinit Nalawade, Nikhil Kotha, Paul J. Riviere, Jason Efstathiou, Rana R. McKay, A. Karim Kader, Brent S. Rose, Tyler F. Stewart

المصدر: European Urology Open Science, Vol 30, Iss , Pp 1-10 (2021)

مصطلحات موضوعية: Muscle-invasive bladder cancer, Radical cystectomy, Trimodal therapy, Bladder preservation, Chemoradiotherapy, Treatment, Diseases of the genitourinary system. Urology, RC870-923, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

العلاقة: http://www.sciencedirect.com/science/article/pii/S2666168321001014Test; https://doaj.org/toc/2666-1683Test

الوصول الحر: https://doaj.org/article/e6a99f1eefd841029f6673fa9a342d8eTest

المؤلفون: Yang, Xixiao, Xue, Xiangdong, Luo, Yan, Lin, Tzu-yin, Zhang, Hongyong, Lac, Diana, Xiao, Kai, He, Yixuan, Jia, Bei, Lam, Kit S, Li, Yuanpei

مصطلحات موضوعية: Medical Biotechnology, Biomedical and Clinical Sciences, Nanotechnology, Colo-Rectal Cancer, Biotechnology, Bioengineering, Digestive Diseases, Cancer, Animals, Antineoplastic Agents, Phytogenic, Camptothecin, Colonic Neoplasms, Combined Modality Therapy, Drug Delivery Systems, HT29 Cells, Humans, Hydrophobic and Hydrophilic Interactions, Irinotecan, Male, Mice, Mice, Nude, Micelles, Nanoparticles, Particle Size, Photons, Photosensitizing Agents, Phototherapy, Rats, Rats, Sprague-Dawley, Time Factors, Xenograft Model Antitumor Assays, Trimodal therapy, Long tumor retention, Drug delivery, "pi-pi" stacking, Nanoporphyrin micelles, “π-π” stacking, Biomedical Engineering, Chemical Engineering, Pharmacology and Pharmaceutical Sciences, Pharmacology & Pharmacy, Pharmacology and pharmaceutical sciences, Biomedical engineering

وصف الملف: application/pdf

الوصول الحر: https://escholarship.org/uc/item/34r5q104Test
https://escholarship.org/content/qt34r5q104/qt34r5q104.pdfTest